New Clinical Data on MorphoSys’s Blood Cancer Drug Candidate MOR208 in NHL and CLL Presented at ASH Annual Meeting
Martinsried/Munich, Germany, December 7, 2015 / B3C newswire / -- MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) today announced clinical data on its proprietary drug candidate MOR208. MOR208 is a potent anti-CD19 antibody with a …